Your browser doesn't support javascript.
loading
Effects of immune modulation therapy on cardiac function in aged patients with chronic heart failure / 中华心血管病杂志
Chinese Journal of Cardiology ; (12): 734-738, 2010.
Article in Chinese | WPRIM | ID: wpr-244176
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the effect of immune modulation therapy on cardiac function and lymphocyte subsets in aged patients with chronic heart failure (CHF).</p><p><b>METHODS</b>CHF (NYHA classification II-IV) patients older than 60 years were randomly divided into two groups CHF intervention group received regular therapy and thymopetide (2 mg/day i.m. for 75 days, n = 48), CHF control group received regular therapy (n = 48), 45 healthy individuals older than 60 years served as normal control. Left ventricular ejection faction of (LVEF), inner diameter of left ventricular end-diastole (LVEDD), inner diameter of left ventricular end-systole (LVESD), lymphocyte subsets, plasma high sensitive C-reactive protein (hsCRP), plasma brain natrium peptide (BNP) and 6 minutes walking distance (6MWT) were measured at before therapy, after the first course (15 days) of treatment and after the third course of treatment (75 days).</p><p><b>RESULTS</b>(1) Before therapy, the levels of BNP, hsCRP, CD8 T cells, LVEDD and LVESD were significantly higher and the levels of CD3, CD4, CD19 T cells, NK, CD4/CD8 ratio, LVEF and 6MWT were significantly lower in CHF patients compared to compared normal controls (all P < 0.05). These parameters were similar between CHF intervention group and CHF control group. (2) At 15 days, the levels of CD3, CD4, CD19 T cells and NK were significantly increased (P < 0.05 or P < 0.01) while the level of CD8, BNP and hsCRP were significantly decreased (P < 0.05 or P < 0.01) in CHF intervention group compared with CHF control group. (3) At 75 days, the levels of CD3, CD4, CD19 T cells, NK, CD4/CD8, LVEF and 6MWT were significantly increased (P < 0.05 or P < 0.01) while the levels of CD8, BNP, hsCRP and Minnesota Living with Heart Failure Questionnaire (MLHFQ) were significantly decreased (P < 0.05 or P < 0.01) in CHF intervention group compared with CHF control group.</p><p><b>CONCLUSION</b>Thymopetide, an immune modulating agent, might regulate the quantity and proportion of lymphocyte subsets and improve cardiac function in aged patients with CHF, indicating that immune modulation therapy might be a new treatment strategy for aged CHF patients.</p>
Subject(s)
Full text: Available Index: WPRIM (Western Pacific) Main subject: Thymosin / C-Reactive Protein / Case-Control Studies / Chronic Disease / Lymphocyte Subsets / Ventricular Function, Left / Therapeutic Uses / Drug Therapy / Allergy and Immunology / Heart Failure Type of study: Observational study Limits: Aged / Aged80 / Female / Humans / Male Language: Chinese Journal: Chinese Journal of Cardiology Year: 2010 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Thymosin / C-Reactive Protein / Case-Control Studies / Chronic Disease / Lymphocyte Subsets / Ventricular Function, Left / Therapeutic Uses / Drug Therapy / Allergy and Immunology / Heart Failure Type of study: Observational study Limits: Aged / Aged80 / Female / Humans / Male Language: Chinese Journal: Chinese Journal of Cardiology Year: 2010 Type: Article